Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovus Pharmaceuticals Inc. (INNV) Message Board

Important Point - In my view: Current outstandi

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 405
(Total Views: 677)
Posted On: 02/10/2017 5:46:06 PM
Posted By: Honeycomb777
Important Point - In my view:

Current outstanding share count sits at 123M plus what will be 25.6M of Novalere's plus probably 11m or so hitting soon from the recent s-1. That in and of itself does not seem too good but let's do some math and think about some things, shall we?


** We were trading for days at .08 when revs were at 1m and o/s was at 48M. Guidance for all of 2017 is $15m WITHOUT FlutiCare.

So, assuming guidance is met (will probably be exceeded) but let's assume 15M revs with 160M o/s by end of year

.08 x 15 divided by 3.3 = .36

Again - this is without FlutiCare folks. Even if you are extremely pessimistic and say that you think a 1-2 r/s is coming by year end, then PPS = .18 (after a built-in 50% selloff) WHICH IS STILL HIGHER than today's PPS.


Now the reasoning part...WHY would FlutiCare not be approved ? Plus if Dr. Damaj and Novalere combined own 51M shares of the say 160M o/s, then 32% of the shares are literally LOCKED DOWN. Sure I suppose they COULD sell some but I think they would be likely not to do it ALL at once, if at all while the company executes on its business plan.

Point being - When FlutiCare is approved - not only do we get a HUGE revenue boost but Novalere will get royalty payments that kick in and would be less likely to sell INNV shares until a likely buyout happens- years down the road.

Currently Damaj and the board own a hair over 20% of the outstanding shares and by registering Novalere's, we will now have 32% of approx 160M LOCKED. This doesn't even count the loyal longs still holding on from 60 cents that haven't sold a share, like me. HMMMMMM, I wonder if Novalere and Bassam are friendly ?


(1)
(0)




Innovus Pharmaceuticals Inc. (INNV) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us